Research field (5)：
Urology
, Hygiene and public health (non-laboratory)
, Hygiene and public health (laboratory)
, Healthcare management, medical sociology
, Pharmacology
Research theme for competitive and other funds (11)：
2022 - 2025 医療データサイエンスによる高齢者医療の疾病構造に関する臨床疫学研究
2019 - 2022 Clinical epidemiological study on disease structure and quality assessment of healthcare for the older population by utilizing healthcare big data
2018 - 2021 Construction of Academic Foundations and Development of a Curriculum for the Creation of Medical Ethics of Hansen's disease
2016 - 2020 Development of a method for validating epidemiological research results using a large-scale claim database.
2012 - 2015 Development of risk table of recurrence after TURBT for non-muscle bladder cancer in Japan using the method of meta-analysis
2011 - 2014 Establishment of new therapeutic protocol for pediatric renal tumor according to the new risk classification
2009 - 2011 Survey of bladder cancer patients-clinical stage, treatment, prognosis and smoking status-
2008 - 2010 Creation of new treatment protocol according to the biological prognostic factors for Wilms Tumor
2006 - 2007 Prediction of in vitro response to interferon-alpha and acquisition of its susceptibility by gene and peptide transduction system
表在性膀胱癌の再発に関する研究
Study on recurrence of superficial bladder cancer
Show all
Papers (222)：
Taketo Kawai, Mizuki Onozawa, Satoru Taguchi, Masaki Shiota, Shinichi Sakamoto, Yoshiyuki Yamamoto, Yasuhide Kitagawa, Tohru Nakagawa, Shiro Hinotsu, Haruki Kume. Changes in the trends of initial treatment for newly diagnosed prostate cancer in Japan: a nationwide multi-institutional study. Japanese journal of clinical oncology. 2024. 54. 9. 1045-1051
Kazuyuki Mori, Shingo Hatakeyama, Hideki Enokida, Hideaki Miyake, Eiji Kikuchi, Hiroyuki Nishiyama, Tomohiko Ichikawa, Takao Kamai, Yasushi Kaji, Haruki Kume, et al. Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association. International journal of urology : official journal of the Japanese Urological Association. 2024. 31. 3. 194-207
Masaki Fujiwara, Yuto Yamada, Tsuyoshi Etoh, Taichi Shimazu, Masafumi Kodama, Norihito Yamada, Takahiro Asada, Shigeo Horii, Takafumi Kobayashi, Teruo Hayashi, et al. A feasibility study of provider-level implementation strategies to improve access to colorectal cancer screening for patients with schizophrenia: ACCESS2 (N-EQUITY 2104) trial. Implementation science communications. 2024. 5. 1. 2-2
Tsukasa Higashionna, Keisaku Harada, Akinari Maruo, Takahiro Niimura, Elizabeth Tan, Quynh Thi Vu, Takayoshi Kawabata, Soichiro Ushio, Hirofumi Hamano, Makoto Kajizono, et al. Trends in Head and Neck Cancer Mortality from 1999 to 2019 in Japan: An Observational Analysis. Cancers. 2023. 15. 15
Masaki Fujiwara, Yuto Yamada, Taichi Shimazu, Naoki Nakaya, Shiro Hinotsu, Maiko Fujimori, Yosuke Uchitomi, Masatoshi Inagaki. Increasing disparities in cancer screening among people with severe mental illness during the COVID-19 pandemic. Schizophrenia research. 2023. 258. 18-20
Yurie Hirata, Madoka Higuchi, Takahiro Osawa, Shiro Hinotsu, Toru Harabayashi, Tango Mochizuki, Nobuyasu Enami, Osamu Nounaka, Yuichiro Shinno, Hiroshi Kikuchi, et al. Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods. International journal of urology : official journal of the Japanese Urological Association. 2022. 203. 10. E1079-E1080
鈴木和浩, 上村博司, 鈴木啓悦, 樋之津史郎, 大家基嗣. Update of treatment strategy with new androgen receptor inhibitors for nonmetastatic castration-resistant prostate cancer (M0CRPC): On the basis of the final overall survival results from the phase III clinical trials including ARAMIS study. 泌尿器外科. 2020. 33. 11
Masanori Noguchi, Kiyohide Fujimoto, Gaku Arai, Hiroji Uemura, Katsuyoshi Hashine, Hiroaki Matsumoto, Satoshi Fukasawa, Hideomi Nakatsu, Atsushi Takenaka, Masato Fujisawa, et al. Personalized peptide vaccination for castration resistant prostate cancer progressing after docetaxel chemotherapy: A randomized, double-blind, placebo controlled, phase III trial. JOURNAL OF CLINICAL ONCOLOGY. 2019. 37. 15
